Methylphenidate for fatigue in ambulatory men with prostate cancer

Cancer

Volumn 116, Issue 21, 2010, Pages 5102-5110

  Roth, Andrew J ^a   Nelson, Christian ^a   Rosenfeld, Barry ^b   Scher, Howard ^a   Slovin, Susan ^a   Morris, Michael ^a   O'Shea, Noelle ^a   Arauz, Gabrielle ^a   Breitbart, William ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b FORDHAM UNIVERSITY   (United States)

Author keywords

Fatigue; Methylphenidate; Prostate cancer; Quality of life; Randomized controlled trial; Symptom control

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TREND STUDY;

AGED; AMBULATORY CARE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FATIGUE; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; PLACEBOS; PROSTATIC NEOPLASMS;

EID: 77956500143     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25424     Document Type: Article

References (59)

1. Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC,. Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med. 2007; 10: 1068 -1075.
2. Forlenza M, Hall P, Lichtenstein P, Evengard B, Sullivan PF,. Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer. 2005; 104: 2022 -2031.
3. Wagner L, Cella D,. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004; 91: 822 -828.
4. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V,. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362: 640 -650.
5. Stone P, Richards M, A'Hern R, Hardy J,. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000; 11: 561 -567.
6. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J,. A randomized, double blind placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with HIV disease. Arch Intern Med. 2001; 161: 411 -420.
7. Smets E, Garssen B, Schuster-Ultterhoeve ALJ, de Haes JCJM,. Fatigue in cancer patients. Br J Cancer. 1993; 68: 220 -224.
8. Stone P, Hardy J, Huddart R, A'Hern R, Richards M,. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000; 36: 1134 -1141.
9. Barnes E, Bruera E,. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer. 2002; 12: 424 -428.
10. Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have chemotherapy. J Natl Compr Canc Netw. 2008; 6: 448 -455.
11. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2008.
12. Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006; 176 (pt 1): 2443 -2447.
13. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK,. Response to low-dose ketoconazole and subsequent dose escalation to high-doe ketoconazole in patients with androgen-independent prostate cancer. Cancer. 206; 107: 975 -981.
14. Bok R, Small EJ,. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999; 20: 451 -458.
15. Kunkel E, Bakker JMR, Myers RE, Oyesanmi O, Gomella LG,. Biopsychosocial aspects of prostate cancer. Psychosomatics. 2000; 41: 85 -94.
16. Zelefsky M, Kelly WK, Scher HI, et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose 3-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol. 2000; 18: 1936 -1941.
17. Monga U, Kerrigan AJ, Thornby J, Monga TN,. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig. 1999; 7: 178 -185.
18. Bruera E, Chadwick S, Brennels C, Hanson J, MacDonald RN,. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treatment Rep. 1987; 71: 67 -70.
19. Breitbart W, Mermelstein C,. An alternative psychostimulant for the management of depressive disorders in cancer patients. Psychosomatics. 1992; 33: 353 -356.
20. Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand S, Davis MP,. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care. 2001; 18: 187 -192.
21. Iop A, Manfredi AM, Bonura S,. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 2004; 15: 712 -720.
22. Kornblith A, Herr HW, Ofman US, Scher HI, Holland JC,. Quality of life of patients with prostate cancer and their spouses: the value of a database in clinical care. Cancer. 1994; 73: 2791 -2802.
23. Portenoy R,. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 1326 -1336.
24. Katon W, Raskind M,. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry. 1980; 137: 963 -965.
25. Kaufmann M, Murray GB, Cassem NH,. Use of psychostimulants in medically ill depressed patients. Psychosomatics. 1982; 23: 817 -819.
26. Fernandez F, Levy J, Galizzi H,. Response of HIV-related depression to psychostimulants: case reports. Hosp Community Psychiatry. 1988; 39: 628 -631.
27. Holmes V, Fernandez F, Levy JK,. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry. 1989; 50: 5 -8.
28. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007; 25: 475 -481.
29. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006; 24: 2073 -2078.
30. Sood A, Barton DL, Loprinzi CL,. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care. 2006; 23: 35 -40.
31. Lower E, Fleishman S, Cooper A, Zeldis J, Faleck H, Manning D,. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and chemobrain in adult cancer patients. J Clin Oncol. 2005; 23 (16 suppl): 8000.
32. Mock V,. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr. 2004;(32): 112 -118.
33. Cullum J, Wojciechowski AE, Pelletier G, Simpson JS,. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004; 49: 139 -144.
34. Bruera E, Brenneis C, Paterson AH, MacDonald RN,. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 1989; 4: 3 -6.
35. Schmitz K, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R,. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1588 -1595.
36. Monga U, Garber SL, Thornby J, et al. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil. 2007; 88: 1416 -1422.
37. Atkinson A, Barsevick A, Cella D, et al. NCCN practice guidelines for cancer-related fatigue. Oncology. 2000; 14: 151 -161.
38. Bruera E, MacDonald RN,. Asthenia in patients with advanced cancer. J Pain Symptom Manage. 1988; 3: 9 -14.
39. Segal R, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009; 27: 344 -351.
40. Culos-Reed S, Robinson JL, Lau H, O'Connor K, Keats MR,. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007; 29: 118 -127.
41. Windsor P, Nicol KF, Potter J,. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004; 101: 550 -557.
42. Segal R, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003; 21: 1653 -1659.
43. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009; 38: 650 -662.
44. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85: 1186 -1196.
45. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD,. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46: 1121 -1123.
46. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361 -370.
47. Beck AT,. Psychiatry: cognitive therapy for depression and panic disorder. West J Med. 1989; 151: 311.
48. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570 -579.
49. Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS,. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992; 12: 3 -10.
50. Chouinard G, Chouinard AR, Aunable L, Jones BD,. Extrapyramidal symptoms rating scale. Can J Neurol Sci. 1980; 3: 233 -238.
51. Gadbury GL, Coffey CS, Allison DB,. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev. 2003; 4: 175 -184.
52. Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G,. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003; 13: 179 -190.
53. Babyak MA,. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004; 66: 411 -421.
54. MacCallum RC, Zhang S, Preacher KJ, Rucker DD,. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002; 7: 19 -40.
55. Royston P, Altman DG, Sauerbrei W,. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006; 25: 127 -141.
56. Guyatt G, Osaba D, Wu AW, Wyrwich KW, Norman GR,. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. 2002; 77: 371 -383.
57. Gross D, Fogg L,. A critical analysis of the intend-to-treat principle in prevention research. J Primary Prev. 2004; 25: 475 -489.
58. Blackhall L, Petroni G, Shu J, Baum L, Farace E,. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med. 2009; 12: 433 -439.
59. Townsley C, Selby R, Siu LL,. Systematic barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23: 3112 -3124.